List of Caprelsa drug patents

Caprelsa is owned by Genzyme Corp.

Caprelsa contains Vandetanib.

Caprelsa has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Caprelsa are:

  • US8642608
  • USRE42353

Caprelsa was authorised for market use on 06 April, 2011.

Caprelsa is available in tablet;oral dosage forms.

Caprelsa can be used as for use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease.

The generics of Caprelsa are possible to be released after 08 August, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(7 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Feb, 2022

(11 months ago)

US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474
Aug, 2028

(5 years from now)

Drugs and Companies using VANDETANIB ingredient

Market Authorisation Date: 06 April, 2011

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic